By Christina T. Loguidice


Optimizing Outcomes With ADCs in Breast Cancer Requires a Tactical Approach

March 8th 2022

Antibody-drug conjugates are innovative and effective therapeutic agents that have transformed the treatment landscape for patients with HER2-positive breast cancer and triple-negative breast cancer.

Combination Strategies Reshape Treatment Paradigm for Advanced Endometrial Cancer

April 19th 2021

As investigators expand their understanding of the biology of endometrial cancer, doors to new treatment approaches are opening, including the use of a variety of combinations that employ targeted therapies and immunotherapies.

Clinical Factors Drive Choice of CDK4/6 Inhibitors for Hormone Receptor–Positive Breast Cancer

March 25th 2021

As CDK4/6 inhibitors solidify their role as the treatment of choice for patients with hormone receptor–positive, HER2-negative breast cancer, an ongoing clinical challenge remains: distinguishing the appropriate agent.

Looking Forward to a New Wave of Breast Cancer Therapies

May 14th 2020

The degree to which nature and nurture affect disease has long been debated in medicine, and it is an issue that esteemed breast cancer researcher and medical oncologist Joyce A. O’Shaughnessy, MD, has been working to unravel for her patients throughout a career that spans more than 30 years.

MRD in Acute Lymphoblastic Leukemia: Why, How, When, and Whom to Test?

May 13th 2020

During a recent OncLive Peer Exchange®, a panel of experts in adult and pediatric leukemias provided an update on minimal residual disease testing in acute lymphoblastic leukemia. 

Test May Detect Pancreatic Cancer Early

May 17th 2010

A novel blood test identifies PAM4 (or clivatuzumab), an antigen that is present in almost 90% of pancreatic cancers and precancers.

Nanotech in 2009: A Fantastic Voyage

May 26th 2009

While the concept of shrinking humans is quite fantastic and unrealistic, scientists have already developed tiny vessels that can hunt down diseased cells and deliver precise drug doses.